Paul Grayson

President and Chief Executive Officer
RuiYi

Mr. Paul Grayson previously served as CEO of Fate Therapeutics, a San Diego-based, privately held biopharmaceutical company focused on the development of therapies that act through stem cell modulation. Before this, he was managing director of Sanderling Ventures where he was a founding board member of multiple portfolio companies including: Calcimedica, Taligen Therapeutics (acquired by Alexion Pharmaceuticals), and Naviscan. Prior to Sanderling, Mr. Grayson served as the founding Chairman and CEO of Senomyx Inc. and part of the founding management team of Aurora Biosciences (acquired by Vertex). He received his M.B.A. from the University of California, Irvine, and his B.A. in Computer Science and Biochemistry from the University of California, Los Angeles.

Check out the incredible speaker line-up to see who will be joining Paul.

Download The Latest Agenda

Day 2

Sunday, April 10th, 2016

13:45 PANEL: Exploring Opportunities And Overcoming Challenges To Do Business In China And Other Emerging Markets

• Determining why there is a big appetite for acquiring companies and licensing in China; how does China factor into biopharma’s plans for the future?

• The Wild, Wild West: Developing a strategy to overcome issues in regulatory approval, reimbursement, and more

• Establishing which product profiles work in China and which do not

• Outlining successes, challenges, and lessons learned in working in China and other emerging markets